Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medicure has said that an analysis of the data from its pivotal Phase III MEND-CABG II clinical trial of company's MC-1 showed that it did not meet the primary endpoint.
Subscribe to our email newsletter
The trial was designed to evaluate the effect of MC-1, versus placebo, on the incidence of cardiovascular death or nonfatal myocardial infarction up to and including 30 days following coronary artery bypass graft or CABG surgery.
Based on the results, the company does not plan on submitting an application for MC-1 marketing approval to the FDA for the CABG indication at this time.